Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by INC Research
Sponsor:
Collaborators:
AbbVie
Apotex Inc.
Aurobindo
Boehringer Ingelheim
Bristol-Myers Squibb
Cipla Ltd.
F.Hoffman-La Roche
Gilead Sciences
Hetero
Janssen R&D Ireland
Lupin Pharmaceuticals
Merck Sharp & Dohme Corp.
Mylan Laboratories
Novartis
Pfizer
Prinston
Ranbaxy Inc.
Sandoz Inc.
Sciegen Pharmaceuticals
Sigmapharm Laboratories
Silarx Pharmaceuticals Inc
Strides Arcolab Ltd.
Sunshine Lake Pharma
Teva Pharmaceuticals USA
ViiV Healthcare
Information provided by (Responsible Party):
INC Research
ClinicalTrials.gov Identifier:
NCT00404989
First received: November 27, 2006
Last updated: March 31, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2099
  Estimated Primary Completion Date: January 2099 (Final data collection date for primary outcome measure)